Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | GGT1 | P19440 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218878 | 1.00 | MMP2 (0.73) | MMP2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL218877 | 1.00 | MMP2 (0.73) | MMP2EPHX1ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL23051768 | 0.98 | MMP2 (0.71) | MMP2EPHX1ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL23051769 | 0.98 | MMP2 (0.71) | MMP2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL4343987 | 0.90 | MMP2 (0.60) | MMP2GGT1 | |
| SCHEMBL4343992 | 0.90 | MMP2 (0.60) | MMP2GGT1 | |
| SCHEMBL20717803 | 0.87 | MMP2 (0.71) | MMP2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL20717933 | 0.87 | MMP2 (0.71) | MMP2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL20630479 | 0.86 | MMP2 (0.69) | MMP2EPHX1ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL20704629 | 0.86 | MMP2 (0.69) | MMP2EPHX1ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626417-A1 | METHODS AND COMPOSITIONS FOR IMPROVING DRIVING PERFORMANCE | AXSOME THERAPEUTICS (US) | 2025-10-08 | — | — | EP | claimed |
| US-12318362-B2 | Methods of providing solriamfetol therapy to subjects with impaired renal function | AXSOME MALTA LTD. (MT) | 2025-06-03 | — | — | US | claimed |
| US-20250152548-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-05-15 | — | — | US | claimed |
| US-20250108030-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-04-03 | — | — | US | claimed |
| US-12194016-B2 | Methods of providing solriamfetol therapy to subjects with impaired renal function | AXSOME MALTA LTD. (MT) | 2025-01-14 | — | — | US | claimed |
| EP-4232428-B1 | NOVEL PROCESS FOR PREPARING SOLRIAMFETOL HYDROCHLORIDE | PROCOS SPA (IT) | 2024-11-13 | — | — | EP | claimed |
| US-20240252462-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-08-01 | — | — | US | claimed |
| EP-4395763-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2024-07-10 | — | — | EP | claimed |
| WO-2024118904-A1 | METHODS AND COMPOSITIONS FOR IMPROVING DRIVING PERFORMANCE | AXSOME THERAPEUTICS (US) | 2024-06-06 | — | — | WO | claimed |
| US-11986455-B2 | Methods of providing solriamfetol therapy to subjects with impaired renal function | AXSOME MALTA LTD. (MT) | 2024-05-21 | — | — | US | claimed |
| CN-109906078-B | Formulations of (R) -2-amino-3-phenylpropylcarbamate | 爵士制药国际III有限公司 | 2022-09-13 | — | — | CN | claimed |
| US-20220000831-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-01-06 | — | — | US | claimed |
| US-11160779-B2 | Methods of providing solriamfetol therapy to subjects with impaired renal function | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-11-02 | — | — | US | claimed |
| US-20210290589-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-09-23 | — | — | US | claimed |
| US-20210205257-A1 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-08 | — | — | US | claimed |
| US-10959976-B2 | Methods and compositions for treating excessive sleepiness | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-03-30 | — | — | US | claimed |
| US-10940133-B1 | Methods of providing solriamfetol therapy to subjects with impaired renal function | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-03-09 | — | — | US | claimed |
| US-10912754-B2 | Methods and compositions for treating excessive sleepiness | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-02-09 | — | — | US | claimed |
| US-20200281886-A1 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2020-09-10 | — | — | US | claimed |
| EP-2496228-B1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SK BIOPHARMACEUTICALS CO LTD (KR) | 2014-01-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152548-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-20200281886-A1 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | CHAT, PNMT, HCRTR1 | MMP2 3312/4885EPHX1 1253/4885ALPI 2786/4885 |
| US-10959976-B2 | Methods and compositions for treating excessive sleepiness | CHAT, PNMT, HCRTR1 | MMP2 3312/4885EPHX1 1253/4885ALPI 2786/4885 |
| US-20220000831-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-12194016-B2 | Methods of providing solriamfetol therapy to subjects with impaired renal function | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-11160779-B2 | Methods of providing solriamfetol therapy to subjects with impaired renal function | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-20210205257-A1 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | CHAT, PNMT, HCRTR1 | MMP2 3312/4885EPHX1 1253/4885ALPI 2786/4885 |
| US-11986455-B2 | Methods of providing solriamfetol therapy to subjects with impaired renal function | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-12318362-B2 | Methods of providing solriamfetol therapy to subjects with impaired renal function | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-20240252462-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-10940133-B1 | Methods of providing solriamfetol therapy to subjects with impaired renal function | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-20210290589-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
| US-10912754-B2 | Methods and compositions for treating excessive sleepiness | CHAT, PNMT, HCRTR1 | MMP2 3312/4885EPHX1 1253/4885ALPI 2786/4885 |
| US-20250108030-A1 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | GLS, GRHPR, AGXT | MMP2 1747/4885EPHX1 1773/4885ALPI 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.